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Abstract
Background: A previous randomised controlled trial (RCT) of patients with chronic low back pain (LBP) and vertebral
bone marrow (Modic) changes (MCs) on magnetic resonance imaging (MRI), reported that a 3-month, high-dose
course of antibiotics had a better effect than placebo at 12 months’ follow-up. The present study examines the effects
of antibiotic treatment in chronic LBP patients with MCs at the level of a lumbar disc herniation, similar to the previous
study. It also aims to assess the cost-effectiveness of the treatment, refine the MRI assessment of MCs, and further
evaluate the impact of the treatment and the pathogenesis of MCs by studying genetic variability and the gene and
protein expression of inflammatory biomarkers.
Methods/design: A double-blinded RCT is conducted at six hospitals in Norway, comparing orally
administered amoxicillin 750 mg, or placebo three times a day, over a period of 100 days in patients with
chronic LBP and type I or II MCs at the level of a MRI-confirmed lumbar disc herniation within the preceding
2 years. The inclusion will be stopped when at least 80 patients are included in each of the two MC type
groups. In each MC type group, the study is designed to detect (β = 0.1, α = 0.05) a mean difference of 4
(standard deviation 5) in the Roland Morris Disability Questionnaire score between the two treatment groups
(amoxicillin or placebo) at 1-year follow-up. The study includes cost-effectiveness measures. Blood samples are
assessed for security measures and for possible inflammatory mediators and biomarkers at different time
points. MCs are evaluated on MRI at baseline and after 12 months. A blinded intention-to-treat analysis of
treatment effects will be performed in the total sample and in each MC type group.
Discussion: To ensure the appropriate use of antibiotic treatment, its effect in chronic LBP patients with MCs
should be re-assessed. This study will investigate the effects and cost-effectiveness of amoxicillin in patients
with chronic LBP and MCs at the level of a disc herniation. The study may also help to refine imaging and
characterise the biomarkers of MCs.
Trial registration: ClinicalTrials.gov, ID: NCT02323412. Registered on 21 November 2014.
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Background
Low back pain (LBP) is considered the single leading
cause for disability worldwide and affects all age groups
from adolescents to the elderly, causing activity limitation
and work absence with subsequently an economic burden
on individuals, families, communities, industry, health ser-
vices and governments [1]. It is generally recognised that
the etiology of LBP is multifactorial, but despite the in-
crease in research over the last 50 years, there is a lack of
knowledge, particularly regarding the interaction between
environmental, biological and genetic factors. The use of
magnetic resonance imaging (MRI) in the assessment of
LBP has increased during the last decade, but in about
80–90% of LBP patients imaging reveals no findings with
clear relevance to treatment choice [2]. In recent years
Modic changes (MCs) have gained attention; these are
MRI signal changes in the vertebral bone marrow extend-
ing from the endplate, and are defined into types I
(oedema type), II (fatty type) and III (sclerotic type) based
on their T1 and T2 signals [3]. MCs have an inconsistent
relationship to LBP [4–9] and an unclear pathogenesis,
which is hypothesised to be mechanical, autoimmune, vas-
cular, inflammatory and/or infectious [10–14].
Systematic reviews reveal that existing treatments for
non-specific LBP have only a small-to-moderate effect
[15–17]. One study assessed antibiotic treatment as a
new treatment for selected patients with persistent LBP
and type I MCs at the level of a previously herniated
intervertebral disc [18]. They hypothesised that a low-
grade infection of the disc by the anaerobic Proprioni-
bacterium acnes bacteria (P. acnes) resulted in adjacent
bone oedema (type I MCs) and chronic disabling LBP.
The hypothesis was based on the investigation of bacter-
ial growth in herniated disc material removed by surgery
[19–21], suggesting that those who developed type I
MCs were more likely to have infection with P. acnes. In
a randomised controlled trial (RCT), 100 days of anti-
biotic treatment with amoxicillin clavulanate tablets was
more effective than placebo in all primary and secondary
outcomes at 12 months’ follow-up [18].
The effect of antibiotic treatment in chronic LBP pa-
tients with MCs should be re-assessed for many reasons.
There are controversies regarding this trial which call
for further research [22–24]. Long-term antibiotic treat-
ment has side effects and may cause antimicrobial resist-
ance and should not be used in a large sub-group of
LBP patients based on a single RCT (16 to 62% of LBP
patients have MCs [25, 26]). Furthermore, the rationale
for the treatment is uncertain. The neovascularisation
associated with disc herniation is thought to allow P.
acnes to enter the disc during ‘normal’ bacteraemia [19,
21], but there is conflicting data on the existence of P.
acnes in discs with or without herniation [23, 24, 27, 28].
The presence of P. acnes in the discs of patients
undergoing spinal surgery ranges from 0 to 86% [24]
and it can also not be excluded that the bacteria found
in nuclear material from discs that have been operated
on may be due to intraoperative contamination rather
than infection [23, 24]. Additionally, the previous trial
only included patients with type I MCs [18]. Until now,
no study has examined whether antibiotic treatment is
effective for patients with type II MCs. Furthermore, the
0.2-Tesla MRI used in the previous study may have
shown substantially more type I MCs and fewer type II
MCs compared with a 1.5-Tesla MRI which is com-
monly used in clinical practice [29]. One may also ques-
tion the relevance of distinguishing between type I and
type II MCs since they may represent different stages of
a common process [3, 30].
The present article details the protocol related to the
main purpose of the current study, which is to examine
the effects of antibiotic treatment in patients with chronic
LBP and type I or type II MCs at the level of a lumbar disc
herniation. The study also aims to assess the cost-
effectiveness of the treatment, refine the MRI assessment
of MCs, and further evaluate the impact of the treatment
and the pathogenesis of MCs by studying genetic variabil-
ity and the gene and protein expression of biomarkers.
These parts of the study are only briefly summarised here.
Methods/design
The study is a multicentre, parallel-group, double-blind,
randomised, placebo-controlled, phase-III trial. Pre-
specified objectives and hypotheses are listed in Table 1.
The Regional Committees for Medical Research Ethics in
Norway (REC South East, reference number 2014-2029)
and the Norwegian Medicines Agency (SLV, reference
number 14/01368-11, EudraCT Number: 2013-004505-
14) have approved the protocol, which is registered at
ClinicalTrials.gov under the identifier: NCT02323412.
The project adheres to the Helsinki Declaration, the ICH-
GCP (Good Clinical Practice) guidelines and the Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines for the transparent reporting of trials. It is monitored
by the Department of Clinical Research Support, Oslo
University Hospital.
Study population and recruitment
Patients with chronic LBP referred to outpatient clinics
at participating hospitals (Oslo University Hospital, Ulle-
vål; Haukeland University Hospital; Bergen; St. Olavs
Hospital, Trondheim; University Hospital of North
Norway, Tromsø and Østfold Hospital Trust, Moss,
Drammen Hospital) are screened for eligibility. Both
conservatively treated patients and patients operated on
for disc herniation more than 12 months prior to inclu-
sion are eligible. In addition, patients registered in the
Norwegian Registry for Spine Surgery who have been
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operated on for disc herniation and report severe LBP at
1-year follow-up in the registry, are eligible. A total of at
least 160 patients will be included and randomised (see
‘Sample size’ section below).
To be included in the trial all participants must satisfy
all of the following inclusion criteria:
 Age between 18 and 65 years
 LBP of more than 6 months duration in the area
below the 12th rib and above the gluteal folds with a
Numerical Rating Scale (NRS) pain intensity score
of ≥ 5 (mean of three 0–10 NRSs: current LBP, the
worst LBP within the last 2 weeks, and the usual/
mean LBP within the last 2 weeks)
 MRI-confirmed lumbar disc herniation within the
preceding 2 years
Table 1 Objectives and hypotheses of the AIM study
Objectives Hypotheses
Main objective Main hypothesis
To evaluate the effect of amoxicillin versus placebo on disease-specific
disability evaluated by the RMDQ at 1-year follow-up in patients with
chronic LBP and MCs type I or II at the level of a previously herniated
disc
Patients with MCs type I or II at baseline in the antibiotic treatment
group report a significantly lower RMDQ score at 1-year follow-up than
patients in the placebo group (hypothesis A)
Secondary objective (SO 1) Secondary hypotheses
To evaluate the effect of amoxicillin versus placebo on RMDQ at 1-year
follow-up separately in patients with type I and type II MCs, respectively
Patients with MCs type I at baseline in the antibiotic treatment group
report a significantly lower RMDQ score at 1-year follow-up than patients
in the placebo group (hypothesis B)
Patients with MCs type II at baseline in the antibiotic treatment group
report a significantly lower RMDQ score at 1-year follow-up than patients
in the placebo group (hypothesis C)
Key supportive (KSOs) and exploratory objectives Further hypotheses
To evaluate the effect of amoxicillin versus placebo on ODI at 1-year
follow-up in the whole cohort of included patients (KSO 2)
Patients with MCs type I or II at baseline in the antibiotic treatment
group report a significantly lower ODI score at 1-year follow-up than pa-
tients in the placebo group (hypothesis D)
To evaluate the effect of amoxicillin versus placebo on LBP intensity at 1-
year follow-up in the whole cohort of included patients (KSO 3)
Patients with MCs type I or II at baseline in the antibiotic treatment
group report a significantly lower LBP intensity NRS score at 1-year
follow-up than patients in the placebo group (hypothesis E)
To evaluate whether the short tau inversion recovery (STIR) signal
(intensity and extent) of MCs on baseline MRI predicts RMDQ score at 1-
year follow-up (KSO 4)
In the antibiotic treatment group, high signal from MCs on STIR at
baseline MRI predicts a lower RMDQ score at 1-year follow-up (hypothesis
F)
To assess whether change in STIR signal (intensity and extent) of MCs
from baseline to 1-year follow-up is related to RMDQ score at 1-year
follow-up (KSO 5)
Reduced signal from MCs on STIR from baseline to 1-year follow-up MRI
is associated with a lower RMDQ score at 1-year follow-up (hypothesis G)
To evaluate the effect of amoxicillin versus placebo on health-related quality
of life (the EQ-5D) at 1-year follow-up in the whole cohort of included pa-
tients (KSO 6)
Patients with MCs type I or II at baseline in the antibiotic treatment
group report significantly better quality of life (EQ-5D) at 1-year follow-up
than patients in the placebo group (hypothesis H)
To evaluate cost-effectiveness of amoxicillin versus placebo at 1-year
follow-up in the whole cohort of included patients
To evaluate the difference in incidence of AEs and SAEs between the two
intervention groups from inclusion to 1-year follow-up in the whole co-
hort of included patients
To investigate the effect of amoxicillin on epigenetic patterns,
longitudinal gene and protein expression, genetic variation, from baseline
to post treatment (100 days after start of treatment) and from baseline to
1 year (12 months’) follow-up in patients with MCs type I or II, and to
evaluate correlations with clinical data
To investigate the effect of amoxicillin on bowel flora, resistant bacteria
and resistance genes
To evaluate whether positive pain provocation tests at baseline predicts
RMDQ score at 1-year (12 months’) follow-up
Secondary clinical outcomes not specified above will be used to explore
hypotheses regarding clinical effects post treatment and 1 year after start
of treatment in the whole cohort and separately in patients with type I
and type II MCs
RMDQ Roland Morris Disability Questionnaire, MCs Modic changes, KSO key supportive objectives, ODI Oswestry Disability Index, LBP Low back pain, NRS
Numerical Rating Scale, STIR short tau inversion recovery, MRI magnetic resonance imaging, AE adverse event, SAE serious adverse event
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 Type I and/or type II MC in the vertebral body
marrow at the same level as the previously herniated
disc. For patients with previous surgery for disc
herniation, the MC has to be located at level that
has been operated on
 Written informed consent
The exclusion criteria are as follows:
 Allergy to penicillin or cephalosporins
 Allergy/hypersensitivity to any of the excipients of
the study drug
 Current pregnancy or lactation
 Kidney (creatinine) or hepatic (ALAT/ASAT)
laboratory values above the normal range
 Phenylketonuria (Følling’s disease)
 Mononucleosis or leukaemia
 Any specific diagnosis that may explain the patient’s
low back symptoms (e.g., tumour, fracture,
spondyloarthritis, infection, spinal stenosis)
 Previous low back surgery (L1–S1) for reasons other
than disc herniation (e.g., fusion, decompression,
disc prosthesis)
 Surgery for disc herniation within the last
12 months
 Previous surgery for disc herniation, but MC located
at level(s) that has/have not been operated on only
 Reservation about the intake of gelatine (the
capsules used to encapsulate the study medicine
contains gelatine, which, among other things, is
produced using ingredients derived from pigs)
 Regular use of glucocorticoids
 Regular use of opioids with the exception of codeine
and tramadol
 Not understanding Norwegian language
 Unlikely to adhere to treatment and/or complete
follow-up (e.g., serious ongoing psychiatric disease,
drug abuse, plans to move)
 Antibiotic treatment within the month preceding
the start of treatment
 Contraindications to MRI (e.g., cardiac pacemaker
electrodes, metal implant in the eye or brain,
claustrophobia)
 Unwilling to participate
The recruiting clinician screens eligible patients for in-
clusion and exclusion criteria and requests a baseline
study MRI to confirm and characterise MCs seen on the
clinical MRI available at screening. The baseline MRI is
performed at the local study site and is independently
evaluated by two study radiologists, who also re-assess
the finding of disc herniation on MRI taken the last
2 years and resolve disagreements relevant to inclusion
in consensus. All study sites use the same MRI protocol
and the same type of 1.5-Tesla MRI scanner. The radiol-
ogists allocate patients to a MCs type I group if baseline
MRI shows type I MCs (primary or secondary type I at
the superior and/or inferior endplate) at a level with disc
herniation in the last 2 years. They allocate patients to a
MCs type II group if baseline MRI shows primary or sec-
ondary type II MCs – but not type I MCs – at a level
with disc herniation in the last 2 years. Disc herniation
is defined as displacement of disc material that is focal,
i.e., involves < 25% of the disc circumference (whereas
bulges involve > 25% and usually extend < 3 mm beyond
the edges of the ring apophyses [31]. Primary (most ex-
tensive) and secondary MC types are defined as type I
(hypointense T1 signal and hyperintense T2 signal), type
II (hyperintense T1 signal and iso/hyperintense T2 sig-
nal) and type III (hypointense T1 and T2 signal) [3, 32].
MCs in the vertebral corners with a diameter ≤ 5 mm
and MCs with craniocaudal size < 10% of the vertebral
height do not qualify for inclusion in the RCT. Treat-
ment starts within 6 weeks after screening and within
4 weeks after the baseline study MRI.
Randomisation and blinding
Eligible patients are randomised to one of two treatments,
amoxicillin or placebo. In order to evaluate treatment ef-
fect in all patients as well as separately in each MC type
group (I/II), inclusion is planned to continue until each
MC type group contains at least 80 patients (see ‘Sample
size’ section below). Stratifying for previous disc surgery
will ensure a balanced distribution of this potential source
of infection between treatment groups (amoxicillin/pla-
cebo). A statistician who is not involved in the trial used
STATA 13 (StataCorp LP, College Station, TX, USA) to
generate the randomisation lists stratified by MC type
group (I/II) and previous disc herniation surgery (yes/no)
with a 1:1:1:1 allocation. This ensures that balanced num-
bers of patients receiving antibiotics or placebo within
each of the four resulting strata. The patient allocation is
performed using the Viedoc™ application. We buy original
amoxicillin tablets (Amimox) directly from the manufac-
turer (Ameda). Kragerø Tablettproduksjon AS, Kragerø,
Norway encapsulates the amoxicillin, and produces and
encapsulates the placebo. The original amoxicillin tablets
are put into a gelatine capsule (Capsugel DB-caps AAel
Swedish orange) consisting of two parts put together and
firmly tightened to make them as difficult to open as pos-
sible. Placebo is put into identical capsules, thus ensuring
that both types of capsule have the same look, feel and
taste. The study medicine is then filled into identical con-
tainers and packed in two different kits, one with capsules
containing amoxicillin and the other with capsules con-
taining placebo. Finally, each container is labelled with a
study number according to the randomisation list. At in-
clusion, the patient receives medicine marked only with
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the study number; the appearance of the containers, label-
ling, and the capsules themselves are thus identical for
both treatment groups. Three containers, each filled with
100 capsules, are handed out to the patient at the start of
intervention. Treatment allocation is concealed for all
people involved in the trial. A list linking the study num-
ber to the active substance is kept at Kragerø Tablettpro-
duksjon AS. The list will be retrieved only at the end of
the study when all the data have been collected and en-
tered into the statistical programme and the analysis of
the effect of the treatment on the main outcome (see
below) is completed.
Treatment interventions
The previous study used amoxicillin-clavulanate 1500/
375 mg/day and 3000/750 mg/day (500/125 mg and
1000/250 mg three times a day) for the low- and high-
dose study arm, respectively [18]. The study indicated a
non-significant trend towards better outcomes in the
high-dose arm at 1-year follow-up, but it was not de-
signed to assess dose response. In Norway, amoxicillin is
only available without clavulanate. European culture
studies of P. acnes do not suggest beta-lactamase [33],
and adding clavulanate might increase the risk of side ef-
fects. Hence, in the present study, patients are rando-
mised to receive encapsulated amoxicillin tablets 750 mg
or placebo three times a day, for 100 days.
Patients are permitted to continue with their usual
LBP therapy (e.g., exercises, physiotherapy, analgesics),
but are encouraged to limit any intake of non-steroidal
anti-inflammatory drugs (NSAIDs) (like ibuprofen or na-
proxen), which may be a significant co-intervention. Pa-
tients treated with drugs potentially causing adverse
interaction with amoxicillin (e.g., allopurinol, digoxin,
anticoagulants or methotrexate) can be included, but al-
ternatives to these drugs are considered during the inter-
vention period. All adjunctive therapy is registered.
Data collection
Data are collected at baseline, during the 100 days of
treatment and during the 9 months after treatment ends
(see Fig. 1 for the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) flow chart).
Hence, patients are embedded in the trial for 1 year after
inclusion. Data are collected regardless of participants’
compliance with the study protocol.
Background data are collected at baseline only and in-
clude patient age, gender, Body Mass Index (BMI), ethni-
city, marital status, educational level, work status, physical
work load, leisure time activity, smoking habits, subjective
health complaints [34], emotional distress (Hopkins Symp-
tom Checklist-25 (HSCL-25)) [35], fear-avoidance beliefs
(Fear Avoidance Beliefs Questionnaire (FABQ) work/phys-
ical activity) [36], LBP history/duration (including previous
treatment, e.g., surgery for disc herniation, physiotherapy,
chiropractic), expectations about treatment effect, and
drawing of pain distribution (localised versus widespread
pain) [37, 38]. In addition, pain provocation tests (springing
test, active flexion/extension of the lumbar spine) and
neurological tests (muscle strength, toe-heel walking, sens-
ibility, reflexes, straight-leg raising, i.e., Lasegue test/reverse
Lasegue test) are structured and registered by a clinician in
a Case Report Form (CRF) at baseline.
Primary outcome
The primary outcome measure is pain and disability
measured by the Norwegian version of the Roland and
Morris Disability Questionnaire (RMDQ) [39, 40]. The
RMDQ scale ranges from 0 to 24; higher scores indicate
worse disability. The RMDQ was also used as the pri-
mary outcome in the previous trial [18].
Secondary outcomes
Secondary clinical outcome measures are pain-related
disability assessed by the Oswestry Disability Index
(ODI) version 2.0 [41], LBP intensity (mean 0–10 NRS
score for current LBP, worst LBP within the last 2 weeks,
and usual/mean LBP within the last 2 weeks), leg pain
last week (0–10 NRS), hours with LBP during the last
4 weeks (range 0–448 h) [18], symptom-specific well-
being (5-point Likert scale) [42, 43], health-related qual-
ity of life (EuroQoL-5D version 2.0) [44], self-reported
days of sick leave, co-interventions (other pharmaco-
logical (ATC-coded) and non-pharmacological treat-
ments), patient’s satisfaction with treatment (5-point
Likert scale) and global perceived effect (7-point Likert
scale). A further secondary outcome measure is the short
tau inversion recovery (STIR) signal of MCs.
Adverse events and safety
Details of adverse events are assessed by the clinician and
are MedDRA-coded in a CRF during the treatment period
(monthly), post treatment and at 1-year follow-up. Haem-
atological parameters, including measures of kidney and
liver function, are assessed monthly during the treatment
period, together with a short clinical evaluation to monitor
side effects (not outcome measures).
Compliance and blinding assessment
Treatment compliance is assessed by capsule counts by
a pharmacist at the last visit within the intervention
period (100 days after start of treatment); in addition,
every week during the intervention period patients are
asked how many days they took the study medication in
the last week (0–7). No other measures (e.g., of blood or
urine) will be used to assess dose compliance. We have
not pre-defined a fixed limit for compliance since this
was not defined in the previous study and 94–5% of the
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Fig. 1 (See legend on next page.)
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patients in that study consumed 95–100% of the tablets
[18]. We will perform primary intention-to-treat (ITT)
analyses of all patients regardless of their compliance.
We may assess the effect of compliance on outcome in
an exploratory analysis.
To assess patients’ blinding to treatment allocation,
patients are asked post treatment (100 days after start of
treatment) and at 1-year follow-up to report which study
medicine they think that they received (antibiotics/pla-
cebo/unsure). The effect of their reports on outcome
will be examined in explorative analysis.
Data integrity
All clinician-reported and patient-reported data are cap-
tured electronically using Viedoc™ (Viedoc™, Pharma
Consulting Group, Uppsala, Sweden), a web-based data
capture system, compliant with all relevant regulations.
The patients enter data in the ViedocMe application
after logging on with their own unique username and
password. An SMS is sent to the patients as a reminder
2 days before the deadline for completing the patient-
reported data. Every week, local study coordinators at
each study site control for data completeness for pa-
tients included at their own clinic. In the case of missing
data, clinicians and/or patients are contacted in order to
discover the cause.
Sample size
The study is designed to assess the treatment effect in
the total sample as well as separately in each MC type
group (I/II). In each MC type group, the study is de-
signed to detect (β = 0.1, two-sided α = 0.05) a mean dif-
ference of 4 (standard deviation (SD) 5) in the RMDQ
score between the two treatment groups (amoxicillin or
placebo) at 1-year follow-up. The SD of 5 is within the
upper range of reported SDs for the RMDQ in patients
with persistent LBP [40, 45–49]. In each MC type group,
these assumptions result in a sample size of 66 (33 in
each treatment group) (http://www.openepi.com/Sam-
pleSize/SSMean.htm). To enable separate analyses in
each of the two MC type groups, we need 132 patients.
(In the total sample, this provides 90% power at two-
sided α = 0.05 to detect a mean difference of 2.8 (SD 5)
in the RMDQ score between the two treatment groups).
Presuming 20% dropouts (26 patients), we will include
80 MC type I patients and 80 MC type II patients. We
plan to continue inclusion until 80 patients are included
in the MC type group that is slowest to recruit, implying
inclusion of at least 80 patients in the other MC type
group and at least 160 patients in total.
Data analysis
The pre-specified hypotheses have a prioritised order
(Table 1), reducing multiple testing problems for the first
hypothesis. A statistician blinded to treatment group will
perform ITT analyses of the treatment effect on the pri-
mary outcome (RMDQ score at 1-year follow-up) in the
total sample and in each MC type group (hypotheses A
(main objective), B and C (secondary objectives), Table 1),
using analysis of covariance (ANCOVA) adjusted for base-
line RMDQ score. The significance level will be 0.05 in
these analyses. Treatment effect evaluated by the second-
ary outcomes ODI and LBP-intensity scores at 1-year
follow-up (hypotheses D and E, Table 1) will also be ana-
lysed using ITT ANCOVA adjusted for baseline score. In
all analyses, we will report the between-group mean differ-
ences with 95% confidence intervals (CIs) and p values.
Secondary ITT analyses of treatment effect are (1) lin-
ear mixed-effects models (LME) for repeated measures
of RMDQ (at baseline and at 3, 6, 9 and 12 months) and
(See figure on previous page.)
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) flow chart. Magnetic resonance imaging (MRI). (1) Baseline MRI
according to the study protocol can be a maximum of 4 weeks old when treatment starts. A follow-up MRI is taken between 12 and 13 months
after treatment start (i.e., 12 to 14 months after baseline MRI); (2) For safety: haematological parameters (leucocytes, thrombocytes, eosinophils,
haemoglobin (Hb) and hematocrit (Ht)) and measures of kidney (creatinine) and liver function (ASAT/ALAT), every month or more frequently if
clinically indicated. For scientific purposes: glucose, white cell counts and C-reactive protein (CRP) for further safety monitoring and evaluation of
inflammatory mechanisms and genetics/epigenetics; (3) Blood pressure, pulse, auscultation of heart and lungs (safety); (4) Age, gender, Body Mass
Index (BMI), ethnicity, marital status, educational level, work status, physical work load, leisure time activity, smoking habits, subjective health
complaints, emotional distress, fear-avoidance beliefs, low back pain (LBP) history/duration (including previous treatment, e.g., surgery for disc
herniation, physiotherapy, chiropractic), expectations about treatment effect, pain drawing; (5) Pain provocation tests (springing test, active
flexion/extension of the lumbar spine) and neurological tests (muscle strength, toe-heel walking, sensibility, reflexes, straight-leg raising, i.e.,
Lasegue test/reverse Lasegue test); (6) Roland Morris Disability Questionnaire, also collected 6 and 9 months after start of treatment; (7) Pain
monitoring (LBP intensity) weekly during treatment period, and at 6 and 9 months after start of treatment; (8) Oswestry Disability Index, leg pain,
hours with low back pain during the last 4 weeks, symptom-specific well-being, health-related quality of life, sick leave, short tau inversion
recovery (STIR) signal of Modic changes; (9) Patient’s satisfaction with treatment (5-point Likert scale) and global perceived effect (7-point Likert
scale); (10) Patients are asked to report which study medicine they think they received (antibiotics/placebo/unsure); (11) Co-interventions
(concomitant medication and non-pharmacological treatments) and sick-listing is monitored monthly also during the follow-up period (100 to
365 days) for health-economical calculations; (12) Embraces patients from two participating hospitals. At day 0, faeces are collected before the first
tablet is administered; (13) Containers and capsules delivered to local ‘Sykehusapotek’ at each participating hospital for return capsule count,
registering of accountability in electronic systems and destruction of the returned study drug
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LBP intensity (at baseline, weekly during the treatment
period, and at 3, 6, 9 and 12 months) and (2) responder
analyses, comparing proportions of patients with > 75%,
> 50% and > 30% reduction in RMDQ score from base-
line to 1-year follow-up between treatment groups (chi-
square tests) and reporting number needed to treat
(NNT) with 95% CI.
For hypotheses F and G (STIR signal of MCs), the primary
analysis will be multiple regression analysis. For hypothesis
H (quality of life), ITTANCOVA adjusted for baseline score
will be used (Table 1). Additionally, we will consider ex-
ploratory per-protocol analyses for all hypotheses.
Missing 1-year data on RMDQ, ODI, LBP intensity
and EuroQoL-5D, respectively, in the ITT ANCOVA
analyses and in the responder analyses will be replaced
using multiple imputation methods.
The research team will not perform interim analyses.
An independent Data Monitoring Committee, blinded to
treatment arm, will analyse the primary outcome meas-
ure (RMDQ) at 1-year follow-up in the first 80 included
patients. They may stop the trial if they detect a mean
difference of > 7.0 in 1-year RMDQ score between the
two treatment arms, adjusted for baseline RMDQ score.
Cost-effectiveness
The cost-effectiveness analysis will compare the potential
effect of the treatment by using the primary outcome
RMDQ and the EuroQoL-5D as measures of effectiveness.
Costs of the study treatment (direct costs) will be esti-
mated using a bottom-up approach. Costs to the health-
care system incurred due to LBP (indirect costs) will be
estimated based on data recorded in a monthly cost diary.
The diary will include number of visits to a general practi-
tioner, physical or manual therapist, medical specialists,
social worker, and alternative therapist; number of days of
hospitalisation and/or rehabilitation; use of medication
(both prescription and over-the-counter medication), and
self-reported days of sick leave. The costs of work absen-
teeism will be estimated as the number of days absent
from work multiplied by the average wage rate.
MRI studies
MRI of the lumbar spine is performed at baseline and 1-
year follow-up and includes T1- and T2-weighted fast spin-
echo images (to assess presence and type of MCs) and STIR
images (to provide fat saturation and test hypotheses F and
G, Table 1). The MRIs also include T1-and T2-weighted
fat-water separation images, diffusion-weighted images, and
T1-weighted, fat-saturated, contrast-enhanced images.
We will determine the reliability (observer agreement) of
different MC characteristics by different MRI methods
(kappa statistics and Bland-Altman plots), and explore the
relationship of different MC characteristics to each other
and to clinical variables and outcomes (multiple regression
analyses). We will also compare change in MC characteris-
tics from baseline to 1-year follow-up between treatment
groups.
Biological and molecular studies
To identify and characterise novel biomarkers for MCs,
we will assess underlying biological and molecular
mechanisms. Epigenetic patterns, gene and protein ex-
pression and genetic variation will be mapped out, eval-
uated in the two treatment groups and for the two MC
types at different time points, and correlated to clinical
data. We will also investigate the impact of amoxicillin
on the faecal flora and the emergence of resistant bac-
teria and resistance genes.
Discussion
This article presents the design and rationale for a double-
blind RCT comparing the effect of amoxicillin and placebo
for patients with chronic LBP and MCs type I or II at the
level of a previously herniated disc. A previous Danish
study found an effect of amoxicillin clavulanate in patients
with type I MCs [18]. If our findings differ, this may con-
tribute to the prevention of inappropriate clinical use of
antibiotics in a large patient population.
Several choices made when designing this study need
discussion. First, the requirement of a prior disc hernia-
tion was due to the fact that bacterial investigations have
almost solely been performed in herniated disc material
[28]. In a biopsy study no viable bacteria were found in
vertebrae affected with large MC type I changes [50]. We
also wished to be able to report conclusive results and
avoid overlooking any treatment effect in patients with
disc herniation, since the Danish trial only included and
found treatment effect in such patients [18]. Including pa-
tients without disc herniation would thus have required a
doubled sample size (equally large groups with and with-
out herniation) and financial support. We could have
abandoned the separate investigation of treatment effect
in each MC type group (which also required a doubled
sample size), but we prioritised this investigation.
Second, and partly in order to re-assess findings in the
Danish trial, we chose treatment with amoxicillin in a simi-
lar dose (750 mg three times a day, average of their high-
and low-doses) and for the same period of time (100 days).
Regarding patient inclusion, since MC type is not a
fixed characteristic (but may depend on MRI magnet
strength), we decided to continue inclusion of both MC
type groups unchanged until the MC type group that is
slowest to recruit contains 80 patients (and the other
MC type group contains at least 80 patients). Otherwise,
we would also have had to exclude and potentially disap-
point many eligible patients after their baseline MRI had
shown MCs of a type no longer needed in the study.
Such patients could potentially demotivate other eligible
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patients from participating in the study, which could re-
duce the representativeness of our study sample. Exclud-
ing patients earlier (prior to baseline MRI) based on MC
type on the non-standardised clinical MRI would have
induced heterogeneous patient selection.
For the sample size calculations we considered a
between-group difference of 4 points on the RMDQ as
the smallest clinically relevant difference. In the Danish
study the difference between the amoxicillin clavulanate
group and the placebo group at the 1-year follow-up was
about 7 RMDQ points. In individual patients we con-
sider a 30% improvement as the smallest clinically im-
portant reduction. However, taking the high dose and
long duration of the antibiotic treatment into account,
the size of the between-group differences, or individual
improvement that is large enough to be considered clin-
ically relevant, is not settled and is an issue open for dis-
cussion. In addition, since our study is designed to
detect the smallest clinically relevant difference separ-
ately in each Modic type group, it may detect a smaller
and irrelevant difference in the total sample. However,
statistically significant differences of < 4 RMDQ points
are not clinically relevant and will not be used as a basis
for recommending antibiotic treatment in the studied
patient groups. In addition, proper use of antibiotics
must be based on interpretation of all relevant data on
benefits and harms from all relevant studies.
Trial status
Participant recruitment was initiated on 6 June 2015
and was ongoing at the time that this paper was
submitted (16 March 2017). The last patient was re-
cruited on 1 September 2017 (treatment started at
29 September 2017). A total of 180 patients are in-
cluded. Data collection is expected to be complete
by September 2018. (Additional file 1).
Additional file
Additional file 1: SPIRIT 2013 Checklist. (DOC 121 kb)
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